Industry-leading behavioral science tool SPURâ„¢ is validated to predict adherence and will be offered through the Clinical ink technology platform
WINSTON-SALEM, N.C., Feb. 18, 2025 /PRNewswire-PRWeb/ -- , a global life science technology company, is expanding its patient engagement solutions with the inclusion into its 21 CFR Part 11 platform of the behavioral assessment tool and the proprietary d.tellsâ„¢ smart AI engine. These digital tools were developed by , validated by extensive published literature, and used in over 40,000 patients across 27 therapeutic areas by multiple large pharmaceutical companies.
Protocol compliance and retention are critical factors for the success of clinical trials. Behavior can be predicted and modified by the SPURâ„¢ digital assessment tool which identifies behavioral drivers unique to each patient. This provides supportive information to the patient, as well as measures of non-adherence risk to investigators. In addition, SPURâ„¢ provides investigators with personalized guidance for each patient, including the communication style and content that will resonate with a specific behavioral phenotype. The benefits encompass optimized engagement and reduced risk of non-adherence, such as reduced drop out from a clinical trial. SPURâ„¢ can be administered either prior to or after consent and then readministered during the trial.
SPURâ„¢ can be further enhanced with the d.tellsâ„¢ AI engine. d.tellsâ„¢ chooses and distributes the most appropriate content and features from the solution library for each patient's behavioral profile. It further refines the personalization by adapting the frequency, duration, and tone of the messages and notifications it sends, according to the patient's sociomedical and behavioral data.
, Chief Medical Officer of Clinical ink commented "I am excited to see the value that SPURâ„¢ will bring to improving adherence, retention, and data integrity in clinical trials. Not only does this validated tool help sponsors comply with FDA guidance on lifestyle standardization in certain therapeutic classes such as GLP-1, but it also offers unique insights to investigators, helping them support participant adherence to the protocol. This predicts and reduces the risk of drop out, preserving study power. I wish SPURâ„¢ had been available during my career as a clinical trialist".
"I'm thrilled that Clinical ink has decided to incorporate SPURâ„¢ into their offering" says , Head of R&D at Observia. "Clinical ink is one of the most forward-thinking clinical trial service providers and their commitment to bring behavioral science into the world of clinical science is proof of this. I strongly believe that thanks to Clinical ink's initiative, trials will now be more efficient, more precise, and far more patient centric. At Observia, we look forward to continuing to support Clinical ink with behavioral science input while we assist our commercial customers post-launch. I can think of no organization that is better suited than Clinical ink to serve as the bridge between clinical and behavioral science".
The terms of the transaction were not disclosed.
About Clinical ink
is the global life science company bringing data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with behavioral science, eDC/Direct Data Capture, eCOA, eConsent, telehealth, and digital biomarkers advancement (including the use of Continuous Glucose Monitoring for detection of hypoglycemia), support the next generation of clinical trials and ultimately, the clinical management of patients.
About Observia
is a Paris-based health tech company founded in 2011 and a pioneer in personalized digital solutions, dedicated to the engagement and support of patients suffering from one or more chronic diseases. The company is the inventor of , a validated, ground-breaking tool for predicting health behavior. Observia's expert teams are committed to improving health outcomes through behavior change, for everyone, everywhere. The solutions developed by Observia are deeply rooted in proven behavioral science and new technologies.
Media Contact
Alissa Dunkin, Clinical ink, 1 (336) 464-0697, [email protected],
SOURCE Clinical ink
Share this article